Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
10 Hints and Deceives to Expand Cell Phone Information Use: Capitalize on Your Information - 2Ober Gabelhorn glacier reveals remains of man missing for over three decades
- 3The Appearance of Experience: Embracing the Reduced Portage Horse
- 4Flu season is underway. What are common symptoms to watch for?
- 5The most effective method to Make a Dazzling Site in 5 Basic Advances
- The 10 Most Famous Works of art Ever
- An Extended period of Voyaging Carefully: the World with Reason
- Map shows more than 1,900 measles cases across U.S.
- Some Americans say they'll go without health insurance as ACA rates spike
- 7 Powerful Techniques to Boost Efficiency with Your Cell Phone: A Thorough Aide
- Von der Leyen: Paris meeting sends signal of unity for Ukraine
- The most effective method to Stay away from Normal Traps While Recruiting a Material Organization
- The most effective method to Amplify Your Opportunity for growth in a Web-based Degree Program
- Pacific voyagers’ remarkable environmental knowledge allowed for long-distance navigation without Western technology
